Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children
BACKGROUND: Longer-term tuberculosis (TB) drug resistance surveillance among children is rare. We determined the prevalence of drug resistance among children with culture-confirmed TB from 2011 to 2013, compared these results with four previous consecutive 2-year periods and documented other mycobac...
Gespeichert in:
| Veröffentlicht in: | The international journal of tuberculosis and lung disease 2016-09, Vol.20 (9), p.1249-1256 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1256 |
|---|---|
| container_issue | 9 |
| container_start_page | 1249 |
| container_title | The international journal of tuberculosis and lung disease |
| container_volume | 20 |
| creator | Schaaf, H. S. Garcia-Prats, A. J. du Preez, K. Rautenbach, C. Hesseling, A. C. |
| description | BACKGROUND: Longer-term tuberculosis (TB) drug resistance surveillance among children is rare. We determined the prevalence of drug resistance among children with culture-confirmed TB from 2011 to 2013, compared these results with four previous consecutive 2-year periods and documented
other mycobacterial isolates identified.METHOD: Surveillance study of mycobacterial culture in all children aged |
| doi_str_mv | 10.5588/ijtld.15.0051 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_27510254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>iuatld/ijtld/2016/00000020/00000009/art00023</ingid><sourcerecordid>1811293862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-2e2898abba14438ad92095d9c060b0d6cbad74795372b4c7509b00af2a788e263</originalsourceid><addsrcrecordid>eNqNkT2P1DAQhiME4o6DkhalpMkytuPYLtHxKZ2EEFBbjj3Z8yqJF9tZafn1OJeFDgk3Mxq_eufjqaqXBHacS_nGH_LodoTvADh5VF0TSXgjFIXHJQcqGiaIuqqepXQAoIQQ8bS6ooKXP95eV-nbEk_ox9HMFutjDCfvMNV-Tn5_n0vMocZjqU0-jGF_rs3s6nREm-My1WGo7TLmJWJjwzz4OKGrp7MNvbEZozdj7XxCk7A41fbejy7i_Lx6Mpgx4YtLvKl-fHj__fZTc_fl4-fbt3eN5QC5oUilkqbvDWlbJo0rSynulIUOenCd7Y0TrVCcCdq3VnBQPYAZqBFSIu3YTfV68y1r_VwwZT35ZHHdFcOSNJFMMEpES_5DSghVTHa0SJtNamNIKeKgj9FPJp41Ab0i0Q9INOF6RVL0ry7WS1_O81f9h0ERfN0Eft7jnI0-hCXO5TDaW-0X82BWSK4g9YnCrDQtJEFSXppAqx0OplDQ2US9_6UTZcXz3b88N8NtRgqkK1Ouj8IlAaVNzGuFsd-j77rG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811293862</pqid></control><display><type>article</type><title>Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Schaaf, H. S. ; Garcia-Prats, A. J. ; du Preez, K. ; Rautenbach, C. ; Hesseling, A. C.</creator><creatorcontrib>Schaaf, H. S. ; Garcia-Prats, A. J. ; du Preez, K. ; Rautenbach, C. ; Hesseling, A. C.</creatorcontrib><description>BACKGROUND: Longer-term tuberculosis (TB) drug resistance surveillance among children is rare. We determined the prevalence of drug resistance among children with culture-confirmed TB from 2011 to 2013, compared these results with four previous consecutive 2-year periods and documented
other mycobacterial isolates identified.METHOD: Surveillance study of mycobacterial culture in all children aged <13 years conducted from March 2011 to February 2013 at the Tygerberg Children's Hospital, Cape Town, South Africa. Drug susceptibility testing against isoniazid (INH) and
rifampicin (RMP) was performed using line-probe assay (GenoType® MTBDRplus). Clinical data were obtained through folder review.RESULTS: Of 381 children, 323 (84.8%; 324 episodes) had Mycobacterium tuberculosis, 46 (12.1%) had M. bovis bacille Calmette-Guérin
and 12 (3.1%) had non-tuberculous mycobacteria isolated. Forty-one (12.7%) children had M. tuberculosis resistant to INH and/or RMP; 15 (4.7%) had multidrug-resistant TB (MDR-TB). The prevalence of INH mono- or polyresistance remained stable; however, RMP monoresistance increased (0/313
in 2003-2005 vs. 6/324, 1.9%, in 2011-2013; P = 0.041); MDR-TB prevalence has declined significantly, from 26/292 (8.9%) in 2007-2009 to 15/324 (4.7%) in 2011-2013 (OR 0.50, 95%CI 0.24-0.99). The prevalence of human immunodeficiency virus co-infection has
decreased significantly, from a peak of 29% to 15.3%.CONCLUSIONS: There has been a significant reduction in bacteriologically confirmed MDR-TB cases. The increase in RMP monoresistance has important implications for treatment.</description><identifier>ISSN: 1027-3719</identifier><identifier>EISSN: 1815-7920</identifier><identifier>DOI: 10.5588/ijtld.15.0051</identifier><identifier>PMID: 27510254</identifier><language>eng</language><publisher>France: International Union Against Tuberculosis and Lung Disease</publisher><subject>Anti-Retroviral Agents - therapeutic use ; Antitubercular Agents - therapeutic use ; Child ; Child, Preschool ; Children ; Coinfection - drug therapy ; Coinfection - epidemiology ; Drug Resistance ; Epidemiological Monitoring ; Female ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; Humans ; Infant ; Isoniazid - therapeutic use ; Male ; Mycobacteria ; Mycobacterium bovis - drug effects ; Mycobacterium bovis - isolation & purification ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Nontuberculous Mycobacteria - drug effects ; Prevalence ; Rifampin - therapeutic use ; South Africa - epidemiology ; Surveillance ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - epidemiology ; Tuberculosis, Multidrug-Resistant - transmission</subject><ispartof>The international journal of tuberculosis and lung disease, 2016-09, Vol.20 (9), p.1249-1256</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-2e2898abba14438ad92095d9c060b0d6cbad74795372b4c7509b00af2a788e263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27510254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schaaf, H. S.</creatorcontrib><creatorcontrib>Garcia-Prats, A. J.</creatorcontrib><creatorcontrib>du Preez, K.</creatorcontrib><creatorcontrib>Rautenbach, C.</creatorcontrib><creatorcontrib>Hesseling, A. C.</creatorcontrib><title>Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children</title><title>The international journal of tuberculosis and lung disease</title><addtitle>Int J Tuberc Lung Dis</addtitle><description>BACKGROUND: Longer-term tuberculosis (TB) drug resistance surveillance among children is rare. We determined the prevalence of drug resistance among children with culture-confirmed TB from 2011 to 2013, compared these results with four previous consecutive 2-year periods and documented
other mycobacterial isolates identified.METHOD: Surveillance study of mycobacterial culture in all children aged <13 years conducted from March 2011 to February 2013 at the Tygerberg Children's Hospital, Cape Town, South Africa. Drug susceptibility testing against isoniazid (INH) and
rifampicin (RMP) was performed using line-probe assay (GenoType® MTBDRplus). Clinical data were obtained through folder review.RESULTS: Of 381 children, 323 (84.8%; 324 episodes) had Mycobacterium tuberculosis, 46 (12.1%) had M. bovis bacille Calmette-Guérin
and 12 (3.1%) had non-tuberculous mycobacteria isolated. Forty-one (12.7%) children had M. tuberculosis resistant to INH and/or RMP; 15 (4.7%) had multidrug-resistant TB (MDR-TB). The prevalence of INH mono- or polyresistance remained stable; however, RMP monoresistance increased (0/313
in 2003-2005 vs. 6/324, 1.9%, in 2011-2013; P = 0.041); MDR-TB prevalence has declined significantly, from 26/292 (8.9%) in 2007-2009 to 15/324 (4.7%) in 2011-2013 (OR 0.50, 95%CI 0.24-0.99). The prevalence of human immunodeficiency virus co-infection has
decreased significantly, from a peak of 29% to 15.3%.CONCLUSIONS: There has been a significant reduction in bacteriologically confirmed MDR-TB cases. The increase in RMP monoresistance has important implications for treatment.</description><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - epidemiology</subject><subject>Drug Resistance</subject><subject>Epidemiological Monitoring</subject><subject>Female</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>Humans</subject><subject>Infant</subject><subject>Isoniazid - therapeutic use</subject><subject>Male</subject><subject>Mycobacteria</subject><subject>Mycobacterium bovis - drug effects</subject><subject>Mycobacterium bovis - isolation & purification</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Nontuberculous Mycobacteria - drug effects</subject><subject>Prevalence</subject><subject>Rifampin - therapeutic use</subject><subject>South Africa - epidemiology</subject><subject>Surveillance</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - epidemiology</subject><subject>Tuberculosis, Multidrug-Resistant - transmission</subject><issn>1027-3719</issn><issn>1815-7920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkT2P1DAQhiME4o6DkhalpMkytuPYLtHxKZ2EEFBbjj3Z8yqJF9tZafn1OJeFDgk3Mxq_eufjqaqXBHacS_nGH_LodoTvADh5VF0TSXgjFIXHJQcqGiaIuqqepXQAoIQQ8bS6ooKXP95eV-nbEk_ox9HMFutjDCfvMNV-Tn5_n0vMocZjqU0-jGF_rs3s6nREm-My1WGo7TLmJWJjwzz4OKGrp7MNvbEZozdj7XxCk7A41fbejy7i_Lx6Mpgx4YtLvKl-fHj__fZTc_fl4-fbt3eN5QC5oUilkqbvDWlbJo0rSynulIUOenCd7Y0TrVCcCdq3VnBQPYAZqBFSIu3YTfV68y1r_VwwZT35ZHHdFcOSNJFMMEpES_5DSghVTHa0SJtNamNIKeKgj9FPJp41Ab0i0Q9INOF6RVL0ry7WS1_O81f9h0ERfN0Eft7jnI0-hCXO5TDaW-0X82BWSK4g9YnCrDQtJEFSXppAqx0OplDQ2US9_6UTZcXz3b88N8NtRgqkK1Ouj8IlAaVNzGuFsd-j77rG</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Schaaf, H. S.</creator><creator>Garcia-Prats, A. J.</creator><creator>du Preez, K.</creator><creator>Rautenbach, C.</creator><creator>Hesseling, A. C.</creator><general>International Union Against Tuberculosis and Lung Disease</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20160901</creationdate><title>Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children</title><author>Schaaf, H. S. ; Garcia-Prats, A. J. ; du Preez, K. ; Rautenbach, C. ; Hesseling, A. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-2e2898abba14438ad92095d9c060b0d6cbad74795372b4c7509b00af2a788e263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - epidemiology</topic><topic>Drug Resistance</topic><topic>Epidemiological Monitoring</topic><topic>Female</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>Humans</topic><topic>Infant</topic><topic>Isoniazid - therapeutic use</topic><topic>Male</topic><topic>Mycobacteria</topic><topic>Mycobacterium bovis - drug effects</topic><topic>Mycobacterium bovis - isolation & purification</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Nontuberculous Mycobacteria - drug effects</topic><topic>Prevalence</topic><topic>Rifampin - therapeutic use</topic><topic>South Africa - epidemiology</topic><topic>Surveillance</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - epidemiology</topic><topic>Tuberculosis, Multidrug-Resistant - transmission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schaaf, H. S.</creatorcontrib><creatorcontrib>Garcia-Prats, A. J.</creatorcontrib><creatorcontrib>du Preez, K.</creatorcontrib><creatorcontrib>Rautenbach, C.</creatorcontrib><creatorcontrib>Hesseling, A. C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The international journal of tuberculosis and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schaaf, H. S.</au><au>Garcia-Prats, A. J.</au><au>du Preez, K.</au><au>Rautenbach, C.</au><au>Hesseling, A. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children</atitle><jtitle>The international journal of tuberculosis and lung disease</jtitle><addtitle>Int J Tuberc Lung Dis</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>20</volume><issue>9</issue><spage>1249</spage><epage>1256</epage><pages>1249-1256</pages><issn>1027-3719</issn><eissn>1815-7920</eissn><abstract>BACKGROUND: Longer-term tuberculosis (TB) drug resistance surveillance among children is rare. We determined the prevalence of drug resistance among children with culture-confirmed TB from 2011 to 2013, compared these results with four previous consecutive 2-year periods and documented
other mycobacterial isolates identified.METHOD: Surveillance study of mycobacterial culture in all children aged <13 years conducted from March 2011 to February 2013 at the Tygerberg Children's Hospital, Cape Town, South Africa. Drug susceptibility testing against isoniazid (INH) and
rifampicin (RMP) was performed using line-probe assay (GenoType® MTBDRplus). Clinical data were obtained through folder review.RESULTS: Of 381 children, 323 (84.8%; 324 episodes) had Mycobacterium tuberculosis, 46 (12.1%) had M. bovis bacille Calmette-Guérin
and 12 (3.1%) had non-tuberculous mycobacteria isolated. Forty-one (12.7%) children had M. tuberculosis resistant to INH and/or RMP; 15 (4.7%) had multidrug-resistant TB (MDR-TB). The prevalence of INH mono- or polyresistance remained stable; however, RMP monoresistance increased (0/313
in 2003-2005 vs. 6/324, 1.9%, in 2011-2013; P = 0.041); MDR-TB prevalence has declined significantly, from 26/292 (8.9%) in 2007-2009 to 15/324 (4.7%) in 2011-2013 (OR 0.50, 95%CI 0.24-0.99). The prevalence of human immunodeficiency virus co-infection has
decreased significantly, from a peak of 29% to 15.3%.CONCLUSIONS: There has been a significant reduction in bacteriologically confirmed MDR-TB cases. The increase in RMP monoresistance has important implications for treatment.</abstract><cop>France</cop><pub>International Union Against Tuberculosis and Lung Disease</pub><pmid>27510254</pmid><doi>10.5588/ijtld.15.0051</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1027-3719 |
| ispartof | The international journal of tuberculosis and lung disease, 2016-09, Vol.20 (9), p.1249-1256 |
| issn | 1027-3719 1815-7920 |
| language | eng |
| recordid | cdi_pubmed_primary_27510254 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Anti-Retroviral Agents - therapeutic use Antitubercular Agents - therapeutic use Child Child, Preschool Children Coinfection - drug therapy Coinfection - epidemiology Drug Resistance Epidemiological Monitoring Female HIV Infections - drug therapy HIV Infections - epidemiology Humans Infant Isoniazid - therapeutic use Male Mycobacteria Mycobacterium bovis - drug effects Mycobacterium bovis - isolation & purification Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Nontuberculous Mycobacteria - drug effects Prevalence Rifampin - therapeutic use South Africa - epidemiology Surveillance Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Multidrug-Resistant - transmission |
| title | Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T18%3A26%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surveillance%20provides%20insight%20into%20epidemiology%20and%20spectrum%20of%20culture-confirmed%20mycobacterial%20disease%20in%20children&rft.jtitle=The%20international%20journal%20of%20tuberculosis%20and%20lung%20disease&rft.au=Schaaf,%20H.%20S.&rft.date=2016-09-01&rft.volume=20&rft.issue=9&rft.spage=1249&rft.epage=1256&rft.pages=1249-1256&rft.issn=1027-3719&rft.eissn=1815-7920&rft_id=info:doi/10.5588/ijtld.15.0051&rft_dat=%3Cproquest_pubme%3E1811293862%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811293862&rft_id=info:pmid/27510254&rft_ingid=iuatld/ijtld/2016/00000020/00000009/art00023&rfr_iscdi=true |